References
- Morgan DA, Ruscetti FW, Gallo R. Selective in vitro growth of T lymphocytes from normal human bone marrows. Science. 1976;193(4297):1007–1008.
- Taniguchi T, Matsui H, Fujita T, et al. Structure and expression of a cloned cDNA for human interleukin-2. Nature. 1983;302(5906):305–310.
- Lotze MT, Change AE, Seipp CA, et al. High-dose recombinant interleukin 2 in the treatment of patients with disseminated cancer: responses, treatment-related morbidity, and histologic findings. JAMA. 1986;256(22):3117–3124.
- Rosenberg SA. IL-2: the first effective immunotherapy for human cancer. J Immunol. 2014;192(12):5451–5458.
- Amaria RN, Reuben A, Cooper ZA, et al. Update on use of aldesleukin for treatment of high-risk metastatic melanoma. Immunotargets Ther. 2015;4:79–89.
- Smith KA. Lowest dose interleukin-2 immunotherapy. Blood. 1993;81(6):1414–1423.
- Brahmer JR, Tykodi SS, Chow LQ, et al. Safety and activity of anti-PD-L1 antibody in patients with advanced cancer. N Engl J Med. 2012;366(26):2455–2465.
- Topalian SL, Hodi FS, Brahmer JR, et al. Safety, activity, and immune correlates of anti-PD-1 antibody in cancer. N Engl J Med. 2012;366(26):2443–2454.
- Pitt JM, Vétizou M, Daillère R, et al. Resistance mechanisms to immune-checkpoint blockade in cancer: tumor-intrinsic and -extrinsic factors. Immunity. 2016;44(6):1255–1269.
- Fares CM, Van Allen EM, Drake CG, et al. Mechanisms of resistance to immune checkpoint blockade: why does checkpoint inhibitor immunotherapy not work for all patients? Am Soc Clin Oncol Educ Book. 2019;39:147–164.
- Jenkins RW, Thummalapalli R, Carter J, et al. Molecular and genomic determinants of response to immune checkpoint inhibition in cancer. Annu Rev Med. 2018;69:333–347.
- Sakaguchi S, Wing K, Miyara M. Regulatory T cells—a brief history and perspective. Eur J Immunol. 2007;37(Suppl 1):S116–S123.
- Horak I. Immunodeficiency in IL-2-knockout mice. Clin Immunol Immunopathol. 1995;76(3 Pt 2):S172–S173.
- Malek TR. The main function of IL-2 is to promote the development of T regulatory cells. J Leukoc Biol. 2003;74(6):961–965.
- Boyman O, Kovar M, Rubinstein MP, et al. Selective stimulation of T cell subsets with antibody-cytokine immune complexes. Science. 2006;311(5769):1924–1927.
- Wang X, Rickert M, Garcia KC. Structure of the quaternary complex of interleukin-2 with its alpha, beta, and gammac receptors. Science. 2005;310(5751):1159–1163.
- Levin AM, Bates DL, Ring AM, et al. Exploiting a natural conformational switch to engineer an interleukin-2 ‘superkine.’. Nature. 2012;484(7395):529–533.
- Sun Z, Ren Z, Yang K, et al. A next-generation tumor-targeting IL-2 preferentially promotes tumor-infiltrating CD8(+) T-cell response and effective tumor control. Nat Commun. 2019;10(1):3874.
- Silva DA, Yu S, Ulge UY, et al. De novo design of potent and selective mimics of IL-2 and IL-15. Nature. 2019;565(7738):186–191.
- Dhupkar P, Gordon N. Interleukin-2: old and new approaches to enhance immune-therapeutic efficacy. Adv Exp Med Biol. 2017;995:33–51.
- Charych D, Khalili S, Dixit V, et al. Modeling the receptor pharmacology, pharmacokinetics, and pharmacodynamics of NKTR-214, a kinetically-controlled interleukin-2 (IL2) receptor agonist for cancer immunotherapy. PLoS One. 2017;12(7):5451–5458.
- Sharma M, Fa’ak F, Janssen L, et al. NKTR-214 enhances anti-tumor T cell immune responses induced by checkpoint blockade or vaccination. J Immunother Cancer. 2017;5(Suppl2; abstr P140):86.
- Bentebibel S-E, Hurwitz ME, Bernatchex C, et al. A first-in-human study and biomarker analysis of NKTR-214, a novel IL2Rβγ-biased cytokine, in patients with advanced or metastatic solid tumors. Cancer Discov. 2019;9(6):711–721.
- Siefker-Radtke AO, Fishman MN, Vasant Balar A, et al. NKTR-214+ nivolumab in first-line advanced/metastatic urothelial carcinoma (mUC): updated results from PIVOT-02. J Clin Oncol. 2019;37:388.
- Diab A, Tykodi S, Curti B, et al. Immune monitoring after NKTR-214 plus nivolumab (PIVOT-02) in previously untreated patients with metastatic Stage IV melanoma. Presented at the Society for Immunotherapy of Cancer 33rd Annual Meeting & Pre-Conference Programs (SITC 2018); 2018 November 6; Washington, DC.
- Diab A, Marcondes M, Cattaruzza F, et al. Phase 1b: preliminary clinical activity and immune activation for NKTR-262 [TLR 7/8 agonist] plus bempegaldesleukin (NKTR-214) [CD122-biased agonist] in patients (pts) with locally advanced or metastatic solid tumors (REVEAL phase 1b/2 trial). Presented at the 2019 ASCO-SITC Clinical Immuno-Oncology Symposium; 2019 March 1; San Francisco.